European Journal of Cancer

Genetic Predisposition to Breast Cancer
pp. 3-3(1)
Author: Ponder B.A.J.

Selective Control of Oncogene Expression in Tumors. Therapeutical Developments
pp. 3-3(1)
Author: Helene C.

Prognostic Factors in Treatment Planning: Use or Abuse?
pp. 3-3(1)
Authors: Bonichon F.; Durand M.

Breast Cancer Imaging
pp. 5-5(1)
Authors: Dilhuydy M.H.; Barreau B.; Henriques C.; Kind M.

Surveillance of a Patient with Metastatic Disease
pp. 5-5(1)
Author: Paridaens R.

Quality Control in Molecular Pathology
pp. 7-7(1)
Author: De Bortoli M.

Genes Predisposing to Breast Cancer
pp. 7-7(1)
Author: Devilee P.

Loss of Heterozygosity and Prognosis
pp. 7-7(1)
Author: Lidereau R.

P53 Mutations and Other Genetic Changes in Invasive and Intraductal Breast Cancer
pp. 7-7(1)
Authors: van de Vijver M.J.; Vos C.J.; ter Haar N.; van der Broek L.J.C.M.; de Leeuw W.J.F.; Clahsen P.C.; van de Velde C.J.H.; Peterse J.L.

The Classification of Ductal Carcinoma in Situ of the Breast
pp. 7-8(2)
Author: Millis R.R.

Imaging of DCIS for Diagnosis and Treatment
pp. 8-8(1)
Author: Gilles R.

SY04 Ductal Carcinomas in Situ: Clinical Trials
pp. 8-8(1)
Authors: EORTC Breast Group E.R.G.; Julien J.P.

DCIS: Quality Control of Conservative Treatment
pp. 8-8(1)
Author: Rutgers E.J.T.

Local Recurrences after Breast Conserving Therapy: Tumor Characteristics
pp. 8-8(1)
Author: Holland R.

Local Recurrences after Breast Conserving Therapy: Therapeutical Factors
pp. 8-9(2)
Authors: Cataliotti L.; Distante V.; Pacini P.; Rontini M.

Impact of Local Control on Survival
pp. 9-9(1)
Author: Kurtz J.

Refinement of the Two Regions on the Long Arm of Chromosome 16 Involved in Breast Cancer
pp. 10-10(1)
Authors: Bonnet-Dorion F.; Hostein I.; de Resende S.; Mautalen S.; Berthier C.; Duboue B.; Lidereau R.; Birnbaum D.; Longy M.

Modulation of Human Stromelysin-3 (ST3) Promoter Activity by Human Breast Cancer Cell Conditioned Medium
pp. 10-10(1)
Authors: Ahmad A.; Mitchell S.; Anglard P.; Basset P.; Hart I.R.

Luminometric Immunoassays of P53 and uPA in 600 Node-Negative Breast Cancers; First Evaluation of the Prognostic Values
pp. 10-10(1)
Authors: Peyrat J.-P.; Vanlemmens L.; Fournier J.; Louchez M.M.; Bonneterre J.

Detection of Isolated Tumor Cells in Peripheral Blood and Bone Marrow in Stage I and II Breast Cancer
pp. 10-10(1)
Authors: Kaaresen R.; Borgen E.; Beiske C.; Quist H.; Guldvaag I.; Schlicting E.; Kvalheim G.; Naume B.

Quantitative Determination of c.erbB.2 Oncoprotein in 1065 Human Breast Tumours by an Enzymoimmunoassay. Comparison with the Clinico-Biological Parameters: A Multicentric Study
pp. 10-11(2)
Authors: Koscielny S.; Daver A.; Wafflart J.; Goussard J.; Ricolleau G.; Rallet A.; Terrier P.; Delarue J.C.

Expression of BCL-2 in Node-Negative Breast Cancer is Associated with Various Prognostic Factors, but does not Predict Response to Peri-Operative Chemotherapy
pp. 11-11(1)
Authors: van Slooten H.-J.; Clahsen P.C.; van Dierendonck J.H.; Duval C.; Pallud C.; Mandard A.-M.; Delobelle-Deroide A.; van de Velde C.J.H.; van de Vijver M.J.

Accumulation of TP53 as Predictor of Response to Chemotherapy of Recurrent Breast Cancer
pp. 11-11(1)
Authors: Berns P.M.J.J.; Foekens J.A.; de Witte H.H.; van Putten W.L.J.; Look M.P.; Willman K.; Meijervan Gelder M.E.; Benraad T.J.; Klijn J.G.M.

Cyclin D1 Expression and Response to Tamoxifen Treatment for Metastatic Breast Cancer
pp. 11-11(1)
Authors: Barnes D.M.; Gillet C.E.; Smith P.; Rubens R.D.

Tumor-Associated Lymphomonocytes from Neoplastic Effusions of Patients with Different Primary Tumors Including Breast Cancers are Able to Release Cytokines
pp. 11-11(1)
Authors: Mantovani G.; Maccio A.; Versace R.; Pisano M.; P. L.; Esu S.; Ghiani M.; Dessi D.; Cherchi R.; Melis G.B.; Del Giacco G.S.

Cytogenetic Analysis in Short Term Culture of Breast Cancer in Korea Women
pp. 11-12(2)
Authors: Bae J.W.; E. S.L.; B. H.K.; Park S.H.; Y. H.C.

Transferrin Receptor (CD71) Expression by Human Breast Cancer Cells
pp. 12-12(1)
Authors: Artamonova E.V.; Vasiliev M.V.; Tupitsyn N.N.; Ognerobov N.A.; Kadagidze Z.G.

Chemotherapy-Induced Diversification of DNA Profiles in Breast Cancer
pp. 12-12(1)
Authors: Zaloudik J.; Janakova L.; Mackova D.; Sheard M.A.; Vojtesek B.

Breast Cancer Cell Mediated Control of Human Stromelysin 3 (ST3) Promoter Activity
pp. 12-12(1)
Authors: Ahmad A.; Marshall J.F.; Mitchell S.; Basset P.; Anglard P.; Hart I.R.

Integrins v1 and v5 Function as Breast Cancer Cell Vitronectin Receptors
pp. 12-12(1)
Authors: Meyer T.; Marshall J.F.; Hart I.R.; Dimbleby R.

Is Cowden Disease Gene a Tumor Suppressor Gene or Not?
pp. 12-12(1)
Authors: Coulon V.; Hostein I.; Bonnet-Dorion F.; Duboue B.; Longy M.

Apoptosis-Loss and Expression of Death-Related Genes in Breast Carcinomas
pp. 12-13(2)
Authors: Sierra A.; Castellsague X.; Coll A.; Manas S.; Escobedo A.; Fabra A.

Circulating Tumor Markers (CEA, MCA, CA 15.3, CA 549) in the Diagnosis Breast Cancer Recurrence after Surgery: 5-Year Results
pp. 13-13(1)
Authors: Zamagni C.; Martoni A.; Cacciari N.; Bellanova B.; Vecchi F.; Pannuti F.

Plasma c-erbB2 Concentrations and Response to Chemotherapy in Breast Cancer
pp. 13-13(1)
Authors: Revillion F.; Hebbar M.; Bonneterre J.; Peyrat J.P.

Determination of Cytosol ERBB-2 Protein in Primary Breast Cancer
pp. 13-13(1)
Authors: Imoto S.; Hasebe T.; Ohkura H.; Sugano K.

Psychosocial Correlates of Oestrogen and Progesterone Receptors in Breast Cancer: Results of Three Consecutive Studies
pp. 13-13(1)
Authors: Razavi D.; Farvacques C.; Heer C.V.; Erbil P.; Paesmans M.; Delvaux N.

Correlational Study of Microangiographic and Immunohistochemical Techniques for Tumour Vascularisation
pp. 13-13(1)
Authors: Dalal A.V.; Martin L.; Holcombe C.; Green B.; Winstanley J.; Leinster S.J.

Non-Invasive Measurement of Antioestrogen Activity in the Breast
pp. 13-14(2)
Authors: Harding C.; Osudenko O.; Tetlow L.; Howell A.; Bundred N.J.

Expression of Thymidine Phosphorylase in Mammary Carcinomas and its Relationship to Angiogenesis
pp. 14-14(1)
Authors: Yoshida H.; Yonenaga F.; Ohi Y.; Takasaki T.; Sagara Y.; Yoshinaka H.; Aikou T.; Akiba S.; Akiyama S.

Prediction of the Effect OF 5'-Deoxy-5-Fluorouridine (5'-DFUR) by the Status of Angiogenic Enzyme Thymidine Phosphorylase Expression in Advanced Breast Cancer Patients
pp. 14-14(1)
Authors: Tominaga T.; Yamamoto Y.; Toi M.

Subclinical Thyroid Dysfunction in Patients with Breast Cancer
pp. 14-14(1)
Authors: Millan J.; Mangas A.; Moran A.; Torres F.; Gorotiza J.R.; Pinilla B.; del Toro J.

Polymorphism of Estrogen Receptors from Primary Breast Cancers
pp. 14-14(1)
Authors: Maaroufi Y.; Hadiy S.; Leclercq G.; Lespagnard L.; Larsimont D.

Localisation of Impalpable Breast Lesions -- A Surgical Approach
pp. 14-14(1)
Authors: della Rovere G.Q.; Morgan M.; Warren R.; Patel A.; Benson J.R.

A Prognostic Index for Breast Ductal Carcinoma in Situ (DCIS)
pp. 14-15(2)
Authors: Silverstein M.J.; Craig P.H.; Lagios M.D.; Waisman J.R.; Colburn W.J.; Poller D.N.

Risk Factors and their Importance in Complications after Breast Surgery
pp. 15-15(1)
Authors: Horby J.; Jorgensen T.; Pilsgaard B.

Diagnosis of Intramammary Recurrences of Breast Cancer after Conservative Treatment
pp. 15-15(1)
Authors: Distante V.; Ciatto S.; Rontini M.; Simoncini R.; Manetti A.; Falli F.; Cataliotti L.

Immediate Breast Reconstruction after Mastectomy for Cancer
pp. 15-15(1)
Authors: Ringberg A.; Tengrup I.

Chest Wall Resection in 44 Patients with Recurrent Breast Cancer: Indications and Results
pp. 15-15(1)
Authors: Rutgers E.J.T.; Faneyte I.F.; Zoetmulder F.A.N.; te Velde A.

Pattern of Lymphatic Dissemination in Breast Cancer
pp. 15-16(2)
Authors: Kapteijn B.A.E.; Nieweg O.E.; Peterse J.L.; Rutgers E.J.T.; Kroon B.B.R.

Axillary Lymphadenectomy Prepared by Fat Aspiration Versus Functional Axillary Lymphadenectomy (FAL): Preliminary Results of a Prospective Randomized Trial
pp. 16-16(1)
Authors: Giard S.; Laurent J.C.; Dron A.

Conservative Approach in Subareolar Breast Cancers: A Series of 37 Patients
pp. 16-16(1)
Authors: Bussieres E.; Guyon F.; Tribondeau P.; Thomas L.; Faucher A.; Durand M.

Radical Mastectomy by Means of a Periareolar Incision Followed by Immediate Reconstruction
pp. 16-16(1)
Authors: Figueira Fo. A.S.S.; Beltrao J.E.; Souza E.H.; Brito M.L.; Cavalcanti Y.; Araujo R.; Santos A.L.

A Prospective Randomized Trial of Short Versus Long Hospital Stay after Surgery for Breast Cancer
pp. 16-16(1)
Authors: Bonnema J.; van Geel A.N.; van Wersch A.; Pruyn J.F.A.; Wiggers T.

Axillary Lymphadenectomy by Lipolysis and Liposuction: A Pilot Study
pp. 16-16(1)
Authors: Brun J.L.; Briex M.; Rousseau E.; Belleannee G.; Brun G.

Breast Conserving Surgery. Is It Too Expensive?
pp. 17-17(1)
Author: Norum J.

Immediate Breast Reconstruction (IBR) in Breast Cancer Patients
pp. 17-17(1)
Authors: Blokhin S.N.; Portnoj S.M.; Lactionov K.P.; Barcanov A.I.; Coptiaeva I.V.; Blokhin N.N.

Pain and Other Symptoms during the First Year after Surgery for Breast Cancer
pp. 17-17(1)
Authors: Tasmuth T.; Smitten K.; Kalso E.

Compressive Bandage and Postoperative Complications to Breast Surgery. A Randomised Trial
pp. 17-17(1)
Authors: Horby J.; Jorgensen T.; Pilsgaard B.

Intra Operative HDR Boost in BCT
pp. 17-17(1)
Authors: Hoekstra C.J.M.; Mak A.C.A.; Bos J.

Breast Cancer in Women over 70
pp. 17-17(1)
Authors: Veys I.; Lorent I.; Hertens D.; Nogaret J.M.

Axillary Lymph Node Dissection for Non-Palpable Breast Cancer -- 314 Cases
pp. 18-18(1)
Authors: Le Bouedec G.; Pomel C.; Kauffmann P.; de Latour M.; Dauplat J.

The Timing of Drainage Removal in Breast Surgery
pp. 18-18(1)
Authors: Amanti C.; Lombardi A.; Manzini A.; Regolo L.; Mauro G.; Lucidi M.; Antonaci A.; Di Paola M.

Breast Reconstruction Following Mastectomy: Our Experience
pp. 18-18(1)
Authors: Galassi G.; Amanti C.; Regolo L.; Lombardi A.; Mauro G.; Lucidi M.; Di Paola M.

Breast surgery without Any Antibiotical Prophylaxis
pp. 18-18(1)
Authors: Amanti C.; Lombardi A.; Manzini A.; Regolo L.; Mauro G.; Lucidi M.; Antonaci A.; Di Paola M.

Changing Attitudes among Surgeons towards Breast-Conserving Treatment of Early Breast Cancer
pp. 18-19(2)
Authors: Voogd A.C.; van Driel O.J.R.; Roumen R.M.H.; Coebergh J.W.W.

Variants of Immediate Breast Reconstruction in Breast Cancer Treatment
pp. 19-19(1)
Authors: Demidov V.P.; Pak D.D.; Yermakov A.V.

Axillary Clearance Without Drainage in Breast Cancer
pp. 19-19(1)
Authors: Stockle E.; Avril A.; Bussieres E.; Tribondeau P.; Tunon de Lara C.; Reboul A.

Axillary Lymphadenectomy without Drainage
pp. 19-19(1)
Authors: Garbay J.R.; Lasry S.; Yacoub S.; Leducq J.; Boudinet A.

The Organ-Keeping Operations in the Treatment of the Breast Cancer T1-2 NO MO
pp. 19-19(1)
Authors: Gantsev S.H.; Gallyamov A.A.; Hanov A.V.; Shtefan N.L.

Seroma as Complication to Surgery in Breast Cancer. Randomized Study Comparing Drainage and Compressive Dressing of the Wound
pp. 19-20(2)
Authors: Guldvog I.; Kaaresen R.

Axillary Dissection for Breast Cancer: Long-Term Functional Results
pp. 20-20(1)
Authors: Tribondeau P.; Bussieres E.; Guyon F.; Stockle E.; Avril A.; Mauriac L.

Ductal Carcinoma in Situ (DCIS) of the Breast: About 706 Cases Examined from 1971 to 1995
pp. 20-20(1)
Authors: de Lara C.T.; Stockle E.; Faucher A.; Bussieres E.; de Mascarel I.; Trojani M.; Bonichon F.; Dilhuydy M.H.; Dilhuydy J.M.; Avril A.

Ductal Carcinoma in Situ: Radiosurgical Conservative Treatment in 122 Cases. Analysis of Local Recurrence Factors
pp. 20-20(1)
Authors: Cutili B.; Vaxman F.; Jaeck D.; Bellocq J.P.; Vaneenoge E.; Renaud R.; Ghnassia J.P.; Barlier-Pagel C.; Janser J.C.

Is Axillary Node Dissection (A.N.D.) Useful for Microinfiltrative Breast Carcinoma (MIBC)?
pp. 20-20(1)
Authors: Floquet A.; Halle O.; Durand M.; Avril A.; Mac Grogan G.; Bonichon F.; Mauriac L.

10 Years Experience in External Beam Radiotherapy and Interstitial HDR 192 Iridium Implantation in the Treatment of Breast Cancer
pp. 20-21(2)
Authors: Hammer J.; Track C.; Seewald D.H.; Zoidl J.P.; Labeck W.; Putz E.; Gruy B.

Risk Factors for Local Recurrence After Breast-Conserving Treatment: Results of a Multicentre Case-Control Study
pp. 21-21(1)
Authors: BCT Study Group; Voogd A.C.

Patterns of Diagnosis of 350 Breast Failures in Patients Treated with Conservative Breast Surgery, Axillary Dissection and RT for Breast Cancer
pp. 21-21(1)
Authors: De Lafontan B.; Resbeut M.; Teissier E.; Hery M.; Cutuli B.; Marchal C.; Achard J.L.; Campana F.; Nguyen T.; Dilhuydy J.M.; Gindrey B.; Mihura J.

Long Term Time Course of Breast Recurrence after Breast-Conservative Treatment of Small Breast Cancer
pp. 21-21(1)
Authors: Giraud P.; Vilcoq J.R.; Campana F.; Clough K.; Fourquet A.

Prognosis after Salvage Treatment for Local-Regional Recurrence of Mastectomy or Breast Conservation in EORTC Trial 10801
pp. 21-21(1)
Authors: van Tienhoven G.; Voogd A.C.; van Dongen J.A.

Acute Toxicities of Concurrent Chemotherapy (CT) & Reduced-Dose Radiotherapy (RT) for Patients Treated with Breast-Conserving Surgery
pp. 22-22(1)
Authors: Recht A.; Shulman L.N.; Come S.E.; Hayes D.F.; Silver B.; Harris J.R.

Patients Experience with Immediate Breast Reconstruction
pp. 22-22(1)
Authors: Rosenquist S.; Sandelin K.; Wickman M.

Intra Operative Iridium versus External Beam Boost in Breast Conservation; Boost Volumes and Local Control
pp. 22-22(1)
Authors: van Tienhoven G.; Schneider C.J.; Hart A.A.M.; Oldenburger F.; Blank L.E.C.M.; Koedooder C.; Taat C.W.; de Jong E.; Gonzalez D.G.

Angiosarcomas of the Breast after Radiation for Carcinoma: 3 New Cases from Institut G Roussy
pp. 22-22(1)
Authors: Molitor J.L.; Spielmann M.; Contesso G.; Arriagada R.; de Vathaire F.

Lymphoedema after Primary Treatment for Breast Cancer in Elderly Women
pp. 22-22(1)
Authors: Tengrup I.; Tennvall L.; Christiansson I.

Local Recurrences (LR) after Radiosurgical Breast Conservative Treatment (BCT): Frequnce, Risk Factors and Outcome
pp. 22-23(2)
Authors: Cutuli B.; Velten M.; Jaeck D.; Renaud R.; Duperoux G.; Rodier J.F.

Is Axillary Dissection Necessary in Breast Cancer Conservative Treatment? An Historical Series
pp. 23-23(1)
Authors: Nogaret J.-M.; Nosbusch M.; Mattheiem W.; Philippson C.; Van Houtte P.

Conservative Treatment for Intraductal Carcinoma of the Breast with Surgery and Radiotherapy
pp. 23-23(1)
Authors: Amichetti M.; Caffo O.; Busana L.; Romano M.; Ambrosini G.; Aldovini D.; Brancato B.; Natale N.; Scalet A.; Tomio L.

Young Age and Breast Conservative Treatment
pp. 23-23(1)
Authors: Moreno F.; Rodriguez D.; Pera J.; Polo A.; Martinez A.; Gomez J.; Rubio E.

Can Pretreatment Mammograms Predict Local Recurrence after Breast-Conserving Therapy?
pp. 23-23(1)
Authors: Voogd A.C.; van der Horst F.; van Beek M.W.P.M.; Crommelin M.A.; Repelaer van Driel O.J.; Coebergh J.W.W.

Axil 95
pp. 24-24(1)
Authors: Avril A.; Mauriac L.; Bonichon F.; Bussieres E.; Stockle E.; Faucher A.

Local Excision with a 10 mm Margin as Sole Treatment for Ductal Carcinoma in Situ (DCIS) of the Breast
pp. 24-24(1)
Authors: Sibbering D.M.; Pinder S.E.; Obuszko Z.; Ellis I.O.; Elston C.W.; Morgan D.A.L.; Robertson J.F.R.; Blamey R.W.

Loco-Regional Recurrences After Mastectomy in Breast Cancer
pp. 24-24(1)
Authors: Jager J.; Volovics L.; Schouten L.; de Jong J.; Hupperets P.; v Meyen-feldt M.; Blijham G.

Hypofractionated Radiotherapy of Breast Cancer in Elderly
pp. 24-24(1)
Authors: Golubicic I.; Borojevic N.; Jelic L.

Risk Factors of Local Recurrence after Breast Conserving Therapy
pp. 24-24(1)
Authors: Elkhuizen P.H.M.; Leer J.W.H.; Fleuren G.J.; van Houwelingen J.C.; Hermans J.M.H.; van de Vijver M.J.

Proliferation Markers in Breast Cancers
pp. 25-25(1)
Authors: Darro F.; Kiss R.

Invasiveness Markers
pp. 25-25(1)
Author: Roos E.

Cell Surface Mucins in the Biology and Treatment of Breast Cancer
pp. 25-25(1)
Authors: Miles D.W.; Burchell J.; Rubens R.D.; Taylor-Papadimitriou J.

Immunohistochemistry as a Tool for New Prognostic Markers
pp. 25-25(1)
Author: Mac Grogan G.

Risk Determination for Good Prognosis Patients
pp. 25-26(2)
Author: Namer M.

Selection of Treatment
pp. 26-26(1)
Author: Pritchard K.I.

Treatment of Operable Breast Cancer in the Elderly
pp. 26-26(1)
Author: Fentiman I.S.

Place of Adjuvant Chemotherapy after 50
pp. 26-26(1)
Author: Roche H.

Skeletal Problems in Postmenopausal Women
pp. 26-26(1)
Author: Tubiana-Hulin M.

Hormone Replacement Therapy
pp. 26-26(1)
Author: Pritchard K.

Influence of Mammographic Patterns on Breast Cancer Screening Performance
pp. 27-27(1)
Authors: van Gils C.H.; Otten J.D.M.; Hendriks J.H.C.L.; Holland R.; Verbeek A.L.M.

Radiation Risk of Mammography Related to Benefit in Screening Programs: A Favourable Balance?
pp. 27-27(1)
Authors: Beemsterboer P.M.M.; Warmerdam P.G.; Boer R.; de Koning H.J.

Reduction of Breast Cancer Mortality Due to Mammographic Screening of Elderly Women
pp. 27-27(1)
Authors: Van Dijck J.A.A.M.; Verbeek A.L.M.; Hendriks J.H.C.L.; Holland R.; Mravunac M.; Werre J.M.

The Yield of an Intensive Follow-Up Program for Women at Increased Risk for Breast Cancer
pp. 27-27(1)
Authors: Rutgers E.J.T.; Hijdendaal M.M.; Peterse J.L.; Besnard A.P.E.

Prognosis in Patients with Carcinoma in Situ of the Breast. A Population Based Study in Sweden
pp. 27-28(2)
Authors: Warnberg F.; Holmberg L.

Germline Mutation at BRCA1 Affects the Histoprognostic Grade in Hereditary Breast Cancer
pp. 28-28(1)
Authors: Sobol H.; Stoppa-Lyonnet D.; Jacquemier J.; Eisinger F.; Longy M.; Vincent-Salomon A.; Kerangueven F.; Noguchi T.; Bailly C.; Birnbaum D.

Early Diagnosis of Inherited Breast Cancer
pp. 28-28(1)
Authors: Moller P.; Maehle L.; Dorum A.; Heimdal K.; Bjorndal H.; Helgerud P.; Quist H.; Karesen R.; Nysted A.; Varhaug J.; Fjosne H.; Guleng R.; Due J.; Bohler P.; Kvinnsland S.; Trope C.

Breast Cancer and In Vitro Fertilization
pp. 28-28(1)
Authors: Jourdain O.; Avril A.; Mauriac L.; Quenel N.; Lajus C.; Bussieres E.; Roux D.; Dallay D.

Ultrasound Guided Fine Needle Aspiration Biopsy (FNAB) for Detection of Axillary Node Metastases: A New Diagnostic Method
pp. 28-28(1)
Authors: Bonnema J.; van Geel A.N.; van Ooijen B.; Mali S.P.M.; Tjiam S.L.; Henzen-Logmans S.C.; Schmitz P.I.M.; Wiggers T.

The Relationship between Early Life Experience and Risk for Breast Cancer in Premenopausal Women
pp. 28-29(2)
Authors: L. J.L.; K. N.W.; J. H.W.; X. J.T.

Results of Mass Screening for Breast Cancer in Atomic Bomb Survivors Resident in Hiroshima
pp. 29-29(1)
Authors: Kuroi K.; Osaki A.; Toge T.; Ito C.

Review of 260 Non Palpable Breast Lesions
pp. 29-29(1)
Authors: Janssen A.; Christiaens M.R.

Stereotaxic Fine-Needle Aspiration Cytology in the Detection of Non Palpable Breast Cysts: An Alternative to Ultrasound Guidance
pp. 29-29(1)
Authors: Barreau B.; Dilhuydy M.H.; Henriques C.; Zennaro H.; Airaud J.Y.; de Mascarel I.

BRCA1 Gene Alterations in Sporadic Breast Cancer
pp. 29-29(1)
Authors: Gomendio B.; Garcia E.; Perez-Carrion R.; Moyano A.; Provencio M.; Cubedo R.; Espana P.; Bonilla F.

Mutational Study of BRCA1 Gene in Familial Breast Cancer
pp. 29-29(1)
Authors: Garcia E.; Gomendio B.; Perez-Carrion R.; Zamora P.; Espinosa E.; Provencio M.; Cubedo R.; Espana E.; Bonilla F.

Use of Positron Emission and Computed Tomography in Evaluation of Brachial Plexopathy in Breast Cancer Patients
pp. 29-30(2)
Authors: Ahmad A.; Barrington S.; Maisey M.N.; Rubens R.D.

Ultrasound-Guided Localisation of Impalpable Breast Lesions
pp. 30-30(1)
Authors: Campbell L.; D'Costa H.; Jones P.A.; Teasdale C.; Watkins R.M.

Imaging of Tumours in Breast Cancer Patients with the Estrogen Receptor Specific Radioligand Z-[I-123]MIVE
pp. 30-30(1)
Authors: Rijks L.J.M.; van Tienhoven G.; Bakker P.J.M.; Veenhof C.H.N.; Noorduyn L.A.; Janssen A.G.M.; van Royen E.A.

Nonpalpable Opacities on Mammograms: Histopathological-Mammographic Correlations of 304 Cases
pp. 30-30(1)
Authors: Cherel P.; Le Doussal V.; De Maulmont C.; Plantet M.M.; Hagay C.

Evaluation of the European Pilot Project in Navarra; A High Breast Cancer Detection Rate in the First Round and a Low Rate in the Second Round
pp. 30-30(1)
Authors: van Marie M.E.; Reep-van den Bergh C.M.M.; Boer R.; Ascunce N.; de Koning H.J.

Overweight and Hormone Receptor Positive Breast Carcinoma in Postmenopausal Women
pp. 30-31(2)
Authors: Weber B.; Luporsi E.

CA 15-3, CEA and TPS for Monitoring Metastatic Breast Cancer Patients -- A Multicenter Study
pp. 31-31(1)
Authors: van Dalen A.; Barak V.; Cremaschi A.; Gion M.; Molina R.; Namer M.; Stieber P.; Sturgeon C.; Einarsson R.

Stereotaxic Large-Core Needle Biopsy of Breast Microcalcifications
pp. 31-31(1)
Authors: Troufleau P.; Netter E.; Stines J.; Leroux-Broussier A.; Parache R.M.; Verhaeghe J.L.

Breast Screening: A 7-Year Experience in the Northeast of France
pp. 31-31(1)
Authors: Netter E.; Aubry C.; Troufleau P.; Stines J.

Second Cancers after Breast Conservative Treatment (BCT)
pp. 31-31(1)
Authors: Cutuli B.; Velten M.; Duperoux G.; Jaeck D.; Renaud R.; Rodier J.F.

Use of Prevention Modalities for Breast Cancer: Survey on 2889 Self-Administrated Questionnaires
pp. 31-31(1)
Authors: Caffo O.; Robbiati S.F.; Tata F.; Sequi I.

Randomised Controlled Trial Comparing the Effectiveness of Rapid Diagnosis and Routine Outpatient Clinics
pp. 31-32(2)
Authors: Dey P.; Bundred N.; Baildam A.; Asbury D.; Hopwood P.; Readman L.; Knox F.; Coyne J.; Richardson J.; Woodman C.B.J.

The Role of Digital Processing Mammography in Diagnosis of Breast Cancer
pp. 32-32(1)
Authors: Tsouskas L.I.; Xydopoulou C.; Damianidou L.; Tsiklitara A.; Vritsios A.

Breast Cancer: A Retrospective Study of Two Ethnic Groups in the Center of Israel
pp. 32-32(1)
Authors: Ben-Aharon U.; Puri J.; Nakar S.; Pfefferman R.

The Improvement of Aspiration Biopsy Cytology by Ultrasound Guided High Power Aspiration
pp. 32-32(1)
Authors: Wakita K.; Kohno N.; Sakoda Y.; Takahashi M.; Sashikata T.

Breast Cancer in Albania: Incidence and Preliminary Results of Screening
pp. 32-32(1)
Authors: Amanti C.; Lombardi A.; Regolo L.; Antonaci A.; Folliero G.; Mazreku A.; Kodra S.; Hadajani X.; Ndoni L.; Di Paola M.

Surveillance for Contralateral Breast Cancer: The Mode of Diagnosis and Subsequent Stage
pp. 32-32(1)
Authors: Kaas R.; Rutgers E.J.T.; Peterse J.L.

Axillary Lymph Nodes in Breast Cancer: Assessment with 'Power' Doppler Ultrasound
pp. 32-33(2)
Authors: Brightmore T.G.J.; Sissons G.R.J.

Breast Screening for Women Aged < 50 -- Results from a Family History Clinic
pp. 33-33(1)
Authors: Kollias J.; Sibbering D.M.; Holland P.A.M.; Evans A.J.; Litherland J.; Wilson A.R.M.; Elston C.W.; Ellis I.O.; Pinder S.; Robertson J.F.R.

The Position of the Internal Mammary Lymphnode Chain by Scintigraphy and Sonography: A Comparative Study
pp. 33-33(1)
Authors: Scheijmans L.; Struikmans H.; Imhof C.; Dalen A.V.; Isselt J.V.

Standards, Options and Recommendations (SOR) Project from the FNCLCC: Non Metastatic Breast Cancer
pp. 33-33(1)
Authors: Blanc-Vincent M.P.; Labreze L.; Mauriac L.; Fervers B.; Philip T.; Bey P.

Screening for BRCA1 and BRCA2 Germline Mutations -- Analysis of 50 Families with Clustering of Cancer
pp. 33-33(1)
Authors: Hogervorst F.B.L.; Brink G.; Hageman S.; Ligtenberg M.; van Asperen C.J.; Menko F.H.; Wigbout G.; Rutgers E.J.T.; van't Veer L.J.

Body Image after Breast Cancer: Results from a Patient Derived Measure
pp. 33-34(2)
Authors: Baxter N.; Goodwin P.; Bombardier C.; Devins G.M.; Toner B.; McLeod R.

Histologic Findings in Prophylactic Mastectomy Specimens from Women with Hereditary Risk Factors
pp. 34-34(1)
Authors: Verhoog L.C.; van Geel A.N.; Henzen-Logmans S.C.; Seynaeve C.; Tilanus-Linthorst M.; Bartels C.C.M.; Meijers-Heijboer M.; Devilee P.; Klijn J.G.M.

The Age Distribution and Biological Characteristics of Interval Cancers in the North West Region of the NHSBSP
pp. 34-34(1)
Authors: Threlfall A.G.; Woodman C.B.J.

Preliminary Analysis of a Randomized Phase II Study of High-Dose Chemotherapy in High-Risk Breast Cancer
pp. 34-34(1)
Authors: Rutgers E.J.T.; Richel D.J.; Baars J.W.; Schornagel J.H.; Borger J.H.; Koning C.C.E.; Rodenhuis S.

Neo-Adjuvant High-Dose FEC Regimen (H-FEC) with G-CSF (G) for Large Early Breast Cancer
pp. 34-34(1)
Authors: Cussac A.L.; Dohollou N.; Rhor A.; Janin N.; Le Cesne A.; Mansouri H.; Spielmann M.

High Dose Chemotherapy (HDCT) with Autologous Blood Cell (BC) Support in Metastatic Breast Cancer (MBC)
pp. 35-35(1)
Authors: Gluck S.; Ho A.D.

Does Tamoxifen (Tam) Increase Bone Resorption in Premenopausal Women?
pp. 35-35(1)
Authors: Bundred N.J.; Naylor K.; Walls J.; Evans G.; Eastell R.; Howell A.

CMF vs Tamoxifen (TAM) Plus Goserelin (GOS) as Adjuvant Treatment of ER Positive (+VE) Pre-Perimenopausal Breast Cancer Patients (PTS). Preliminary Results of an Ongoing Italian Breast Cancer Adjuvant Study Group (GROCTA) Trial
pp. 35-35(1)
Authors: Boccardo F.; Rubagotti A.; Amoroso D.; Mesiti M.; Geraci O.; Delia P.; Villa E.; Aldrighetti D.; Genta F.; De Sanctis C.; Irtelli L.; Donati D.; Pacini P.; Scotto T.; Schieppati G.

Castration and Tamoxifen Versus Chemotherapy (FAC) for Premenopausal, Node and Receptors Positive Breast Cancer Patients: A Randomized Trial with a 7 Years Median Follow Up
pp. 35-35(1)
Authors: Roche H.; Mihura J.; de Lafontan B.; Reme-Saumon M.; Martel P.; Dubois J.-B.; Naja A.

Interest of Irradiation and AVCF Chemotherapy in 241 Node-Positive Stage II Breast Cancers: Late Results
pp. 35-35(1)
Authors: Charrier S.; Achard J.L.; Auvray H.; Ferriere J.P.; Courtadon M.; Chollet P.

Atlas: An International Megatrial of Tamoxifen Duration
pp. 36-36(1)
Authors: Davies C.; Gray R.; Peto R.

Impact of Adjuvant Chemotherapy in Conservative Treatment of Breast Cancer T1-2N0M0
pp. 36-36(1)
Authors: Semiglazov V.F.; Chagunava O.L.; Moiseyenko V.M.; Barash N.Y.; Ivanova O.A.; Ivanov V.G.

Direct Comparisons of Adjuvant Chemo-Endocrine Therapy in Operable Breast Cancer Stratified by ER and Menopausal Status
pp. 36-36(1)
Authors: Nomura Y.; Tashiro H.; Shirouzu M.; Takayama T.

High Dose Mitoxantrone and Cyclophosphamide with GM-CSF in First Line Chemotherapy of Breast Cancer
pp. 36-36(1)
Authors: Astone A.; Ferro A.; Torino F.; Noviello M.R.; Cassano A.; Barone C.

Intensive Chemotherapy Program with Autologous Bone Marrow Transplantation (ABMT) in Non Metastatic Inflammatory Breast Cancer: Mature Results
pp. 36-36(1)
Authors: Roche H.; Chevreau C.; Mihura J.; Facchini T.; Reme J.M.; Marre A.; Bonnet F.; de Lafontan B.; Bugat R.

Radical Radiotherapy and Effects of Tamoxifen in Patients with Histologically Positive Stumps After Breast Preservation Operations
pp. 36-37(2)
Authors: Kusama M.; Kaise H.; Aoki T.; Koyanagi Y.; Nakamura Y.; Matsunaga T.

FEC-75 Plus G-CSF in Locally Advanced Breast Carcinoma
pp. 37-37(1)
Authors: Artal A.; Alonso V.; Gallego O.; Herrero A.; Tres A.; Isla D.; Delgado M.; Anton-Torres A.

Postoperative Adjuvant Randomized Trial Comparing Chemoendocrine Therapy, Chemotherapy and Immunotherapy for Patients with Stage II Breast Cancer
pp. 37-37(1)
Authors: Morimoto T.; Ogawa M.; Orita K.; Sugimachi K.; Toge T.; Dohi K.; Nomura Y.; Monden Y.; Ogawa N.

A Study of Postoperative Adjuvant Chemotherapy of 5'-DFUR in Breast Cancer Patients (1st Report) -- On Compliance and Safety -- ''The 5'-BC Study Group'' (5'-DFUR Adjuvant Chemotherapy for Breast Cancer Study Group)
pp. 37-37(1)
Authors: Koyama H.; Abe O.; Uchino J.; Hayasaka W.; Abe R.; Izuo M.; Enomoto K.; Tominaga T.; Watanabe H.; Yoshida M.; Taguchi T.; Senoo T.; Toge T.; Monden Y.; Hattori T.; Nomura Y.; Sugimachi K.; Nakazato H.; Ohashi Y.; Miura S.; Morimoto T.; Asaishi K.; Kimijima I.; Ohta J.; Sonoo H.; Toi M.; Yamaguchi S.

High-Dose Cyclophosphamide (CTX), Mitoxantrone (MXT), and Paclitaxel (Taxol(R), TXL) for the Treatment of Metastatic Breast Cancer (MBC) with Blood Cell Support
pp. 37-37(1)
Authors: Gluck S.; Arnold A.; Cano P.; Dorreen M.; Germond C.; Lopez P.; Dulude H.; Gallant G.

Adjuvant Epirubicin and CMF +/- Hormonotherapy in More than 3 Nodes Positive Breast Cancer Patients: Preliminary Data
pp. 37-38(2)
Authors: de Matteis A.; 'Aiuto G.D.; Rinaldo M.; Landi G.; Montedoro D.; Nuzzo F.; Labonia V.; Falco I.; Frezza P.

Intensification Chemotherapy (IQ) with Autologous Peripheral Blood Progenitor Cell (PBPC) Support in Patients with Breast Cancer: Results of the Transplantation Procedure
pp. 38-38(1)
Authors: Constenia M.; Garcia-Arroyo F.R.; Ozores R.; Lorenzo I.; Castro A.; Solla E.

Time Since Birth is a Prognostic Factor in Primary Breast Cancer
pp. 38-38(1)
Authors: Kroman N.; Nielsen J.W.; Andersen K.W.; Mouridsen H.T.; Westergaard T.; Melbye M.

Incidence and Prognostic Value of Routine Clinical Parameters in 2273 Patients with Primary Breast Cancer Treated between 1978-1990
pp. 38-38(1)
Authors: Klijn J.G.M.; Look M.; Meijer-van Gelder M.; Seynaeve C.; Bontenbal M.; van Geel A.N.; Henzen-Logmans S.C.; van Putten W.L.J.; Foekens J.A.

The Selection of Patients with DCIS for a Clinical Randomised Trial: Differences between Large Participating Centres
pp. 38-39(2)
Authors: Bijker N.; Peterse J.L.; Rutgers E.J.T.; Julien J.P.; Cataliotti L.; Mauriac L.

Prognostic Significance of Obvious Peritumoral Emboli in 2692 Primary Operable Breast Carcinoma
pp. 39-39(1)
Authors: de Mascarel I.; Durand M.; Mauriac L.; Bonichon F.; Grogan G.M.; Soubeyran I.; Picot V.; Coindre J.M.; Trojani M.

Does Semi-Quantitative Evaluation Improve the Prognostic Value of Histological Grade in Breast Carcinoma: Comparison of Scarff-Bloom-Richardson (SBR) and Elston-Ellis (EE) Grading Systems in a Series of 825 Cases with a Follow-Up of 10 Years
pp. 39-39(1)
Authors: Zafrani B.; Genestie C.; Asselain B.; Fourquet A.; Rozan S.; Validire P.; Vincent-Salomon A.; Sastre-Garau X.

The Prognostic Importance of Tumour Grade in Lymph Node Positive Breast Cancer
pp. 39-39(1)
Authors: Kollias J.; Elston C.W.; Ellis I.O.; Robertson J.F.R.; Blamey R.W.

Automated Grading in a Prognostic Index
pp. 39-39(1)
Authors: Kohlhardt S.R.; Blamey R.W.; Pinder S.E.; Ellis I.O.; Elston C.W.

Prediction of Tumor Response to Neoadjuvant Chemotherapy in Operable Breast Cancer
pp. 39-39(1)
Authors: Briffod M.; Tubiana-Hulin M.; Spyratos F.; Hacene K.; Rouesse J.

Prognostic Significance of Epidermal Growth Factor Receptor and Estrogen Receptor in Advanced Breast Cancer
pp. 39-40(2)
Authors: Gaafar R.M.; Zikri Z.K.; El Zawahri H.; Eissa S.; Khaled H.M.; El Attar I.; Zaki M.

Diabetes Mellitus -- A Prognostic Factor in Breast Cancer?
pp. 40-40(1)
Authors: Schmidt G.; Noder W.; Clemm C.; Fink M.; Unterburger P.

Prognostic Significance of P53 Protein Accumulation in Male Breast Cancer (MBC)
pp. 40-40(1)
Authors: Massidda B.; Ionta M.T.; Porcu G.; Calo P.G.; Dessalvi P.; Tarquini A.

Histopathological Characteristics of Ductal Carcinoma in Situ (DCIS) of the Breast. A Comparison before and after the Introduction of Mammographic Screening
pp. 40-40(1)
Authors: Idvall I.; Andersson C.; Fallenius G.; Ferno M.; Ingvar C.; Ringberg A.; Thorgeirsson H.

Significance of Some Morphological Signs for Treatment Results in Breast Cancer T1-2N0M0 Patients
pp. 40-40(1)
Authors: Ermilova V.D.; Portnoj S.M.; Repetiuk D.V.; Korotkih I.Y.; Balakireva G.V.; Akhmetov M.S.; Laktionov K.P.; Letyagin V.P.

32P Relative Uptaking by a Tumor (32PRUT) is a Factor of Prognosis in Breast Cancer (BC) Patients
pp. 40-41(2)
Authors: Portnoj S.M.; Laktionov K.P.; Letyagin V.P.; Gaboonia R.I.; Go V.P.; Shiriaev S.V.

The Levels of Estrogen Receptors (ER) and Progesterone Receptors (PR) and Treatment Results in Breast Cancer (BC) T1-2N0M0 Patients
pp. 41-41(1)
Authors: Kushlinsky N.E.; Portnoj S.M.; Repetiuk D.V.; Kuzmina Z.V.; Gershtein E.S.; Balakireva G.V.; Akhmetov M.S.; Laktionov K.P.; Letyagin V.P.

Prediction of Relapse in Patients with Breast Cancer by Blood Flow Analysis Using Color Doppler Ultrasound
pp. 41-41(1)
Authors: Konishi Y.; Hashimoto T.; Kajiwara T.

Psychological Factors as Prognosticators in Metastatic Breast Cancer
pp. 41-41(1)
Authors: Jensen A.B.; Rose C.

Estrogen-Induced Proteins in Breast Carcinoma
pp. 41-41(1)
Authors: Nikolic-Vukosavljevic D.; Adanja-Grujic G.; Brankovic-Magic M.; Polic D.; Mitrovic L.

Pre-Operative Diagnosis and Establishment of Breast Cancer Phenotypic Features of Prognostic Relevance on Routine Fine-Needle Cytological Samples
pp. 41-41(1)
Authors: Lesec G.; De Maublanc M.A.; Richard-Coulet E.; Collet J.F.; Remvikos Y.

Survival Following First Episode of Hypercalcaemia in Breast Cancer Patients
pp. 41-42(2)
Authors: Kristensen B.; Ejlertsen B.; Mouridsen H.T.

Preoperative Values of CA 15.3 and Disease-Free Interval (DFI) in Breast Cancer
pp. 42-42(1)
Authors: Mijailovic M.; Filipovic S.; Filipovic S.

Breast Cancer Outcome after Pregnancy
pp. 42-42(1)
Authors: Halle O.; Floquet A.; Stockle E.; Mauriac L.

DNA Image and Flow Cytometry Analyses in Breast Cancer Fine-Needle Cytopunctures
pp. 42-42(1)
Authors: Spyratos F.; Briffod M.

A Retrospective Analysis of 124 Cases on the Different Clinical Outcome for Patients with ER-/PR+ Breast Tumors as Compared with ER-/PR-
pp. 42-42(1)
Authors: Roy J.A.; Jacob F.; Leclerc G.; Piccart M.J.

Oestrogen Receptor Mutations and Variant Forms
pp. 43-43(1)
Authors: Dowsett M.; Daffada A.; Chan C.; Wooster R.; Stratton M.; Johnston S.R.D.

Growth Factor Receptors
pp. 43-43(1)
Authors: Klijn J.G.M.; Berns P.M.J.J.; Foekens J.A.

IGF₁, GH an Prolactin Receptors in Human Breast Cancer
pp. 43-43(1)
Authors: Peyrat J.P.; Djiane J.; Bonneterre J.

New Cytotoxic Agents Active in Breast Cancer (BC)
pp. 43-43(1)
Author: Eisenhauer E.A.

New Hormonal Agents
pp. 43-44(2)
Author: Paridaens R.

New Drugs Other than Chemotherapeutic or Hormonal Agents: The Hope for Innovative Treatment Strategies Against Breast Cancer
pp. 44-44(1)
Author: Piccart M.J.

New Bisphosphonates
pp. 44-44(1)
Author: Coleman R.E.

Communication between Breast Cancer Patients and Physicians
pp. 44-44(1)
Author: Fallowfield L.J.

Quality of Life of Women in EORTC Trials
pp. 44-44(1)
Author: Kiebert G.M.

Phase II Study of Liarozole in Advanced Breast Cancer Patients
pp. 45-45(1)
Authors: Roy J.A.; Klijn J.; Beex L.; Mauriac L.; Coleman R.; Hoctin-Boes G.; Van Vreckem A.; Piccart M.J.

Neoadjuvant Chemotherapy by VEC Regimen in Breast Cancer. Preliminary Results of a Phase II Trial
pp. 45-45(1)
Authors: Dohollou N.; Floquet A.; Pigneux A.; Mauriac L.; Chauvergne J.; Durand M.

Epirubicin (E) Plus Paclitaxel (P) in Advanced Breast Cancer: A Regimen with High Activity and Low Cardiac Toxicity which Mobilizes Peripheral Blood Stem Cells
pp. 45-45(1)
Authors: Conte P.F.; Michelotti A.; Baldini E.; Salvadori B.; Gennari A.; Tibaldi C.; Pazzagli I.; Bengala C.; Gentile A.

Phase I/II Study of Taxol(R) (paclitaxel) in Combination with Epirubicin and Cyclophosphamide without G-CSF as a First Line Treatment of Metastatic Breast Carcinoma (MBC)
pp. 45-45(1)
Authors: Hulin M.T.; Catimel G.; Bonneterre J.; Soares J.A.; Chazard M.

Phase II Study of Paclitaxel (P) and Epirubicin (E) as First-Line Therapy in Patients (PTS) with Metastatic Breast Cancer (MBC)
pp. 46-46(1)
Authors: Thomssen C.; Luck H.-J.; du Bois A.; Lisboa B.; Untch M.; Kohler G.; Hecker D.; Diergarten K.

Dose Dense Epirubicin (E) and Paclitaxel (P) with G-CSF in Metastatic Breast Cancer (MBC)
pp. 46-46(1)
Authors: Nortier J.; Wils J.; Erdkamp F.; Lalisang R.; Wals J.; Hillen H.; Blijham G.

Taxol. (Paclitaxel), Epirubicin and Cyclophosphamide (TEC) in the Treatment of Metastatic Breast Cancer (MBC): Preliminary Results of a Phase I Study
pp. 46-46(1)
Authors: Nabholtz J.-M.; Khoo K.; Al-Tweigeri T.; Smylie M.; Dudgeon D.; Keller O.; Foerster J.; Olweny C.; Shore T.; Sansregret E.; Stiles E.; Dulude H.; Gallant G.

Hexadecyl Phosphocholine in the Topical Treatment of Skin Metastasized Breast Cancer
pp. 46-46(1)
Authors: Gaafar R.M.; Hamza M.R.; El Mawla N.G.

Weekly Vinorelbine (VRB) as Single Agent for Advanced Breast Cancer (ABC)
pp. 46-46(1)
Authors: Santoro A.; Maiorino L.; Santoro M.

A Phase II Trial on High Dose (240 MG) Toremifene in the Treatment of Advanced Breast Cancer
pp. 47-47(1)
Authors: Baltina D.; Hietanen T.; Johansson R.; Numminen S.; Hakala T.; Helle L.; Valavaara R.; Hajba A.

Phase I Study of Combination Docetaxel with Cyclophosphamide in the Treatment of Metastatic Breast Cancer
pp. 47-47(1)
Authors: Enomoto K.; Abe R.; Fukuda M.; Haga S.; Iino Y.; Ikeda T.; Kimijima I.; Shimizu T.; Yamazaki S.; Taguchi T.

Dose-Finding Study of Weekly Oral Vinorelbine (VRL) in Patients (PTS) with Advanced Breast Cancer (ABC): Preliminary Results
pp. 47-47(1)
Authors: Chevallier B.; Bonneterre J.; Hurteloup P.; Focan C.; Mauriac L.; Piccart M.; Favreau E.; Senac I.

Phase I-II Trial of Mitoxantrone (M) and Taxol (T) in Advanced Breast Cancer (ABC)
pp. 47-47(1)
Authors: Di Costanzo F.; Sdrobolini A.; Bilancia D.; Farabi R.; Angiona S.; Gasperoni S.; Bartolucci R.; Giustini L.; Acito L.; Manzione L.

Third-Line Chemotherapy with Bendamustin for Metastatic Breast Cancer -- A Prospective Pilot Study
pp. 47-47(1)
Authors: Jamitzky T.; Lange O.F.

Org-OD14 Significantly Inhibits DMBA Induced Mammary Tumor Growth in Rats: Effects of Combination Therapy with Tamoxifen or the Antiprogestin Org-31710
pp. 47-48(2)
Authors: Setyono-Han B.; Foekens J.A.; Sander H.J.; Deckers G.H.; Klijn J.G.M.

Cardioxane Still Induces Effective Cardioprotection in Anthracycline Pretreated Breast Cancer Patients
pp. 48-48(1)
Authors: Maral J.; Vinke J.; Oskam R.; Cyrus P.; Plas K.V.; Herrera A.

Paclitaxel and Carboplatin with G-CSF Support in Advanced Breast Cancer Resistant to Anthracyclines
pp. 48-48(1)
Authors: Aravantinos G.; Athanassiadis A.; Giannakakis T.; Bafaloukos D.; Vlachostergiou P.; Briassoulis E.; Kosmidis P.; Pavlidis N.; Skarlos D.; Fountzilas G.

Paclitaxel Combinations with Weekly High Dose 5-FU/Folinic Acid and Cisplatin in the Treatment of Metastatic Breast Cancer -- There is a Possible Role of Combining Paclitaxel with Anthracycline Non Cross Resistant Chemotherapeutic Agents in the First and Second Line Treatment I
pp. 48-48(1)
Authors: Klaassen U.; Wilke H.; Strumberg D.; Pari C.P.; Muller C.H.; Achterrath W.; Harstrick A.; Diergarten K.; Seeber S.

Combined Estrogen Suppression and Receptor (ER) Blockade by Buserelin (LHRH-A) and Tamoxifen (TAM) in Premenopausal Metastatic Breast Cancer: Preliminary Results of a 3-Arm Randomized Study (EORTC 10881)
pp. 49-49(1)
Authors: Klijn J.G.M.; Seynaeve C.; Beex L.; Mauriac L.; van Zijl J.; Veyret C.; Wildiers J.; Jassem J.; Burghouts J.; Becquart M.; Namer M.; Piccart M.; Garcia-Conde J.; Mignolet F.; Hoctin-Boes G.

First Line Tamoxifen for Invasive Hormonal Sensitive Non Metastatic Breast Carcinomas in Young Postmenopausal Patients
pp. 49-49(1)
Authors: Mauriac L.; Durand M.; Bonichon F.; Floquet A.

Double-Blind Trial in Postmenopausal (PMP) Women with Advanced Breast Cancer (ABC) Showing a Dose-Effect and Superiority of 2.5 mg Letrozole Over Megestrol Acetate (MA)
pp. 49-49(1)
Authors: Letrozole International Trial Group AR/BC2.; Smith I.; Dombernowsky P.; Falkson G.; Leonard R.; Panasci L.; Bellmunt J.; Bezwoda W.; Gardin G.; Gudgeon A.; Chaudri H.A.; Hornberger U.

An Open, Comparative Randomized Trial Comparing Formestane vs Oral Megestrol Acetate as a Second-Line Therapy in Postmenopausal Advanced Breast Cancer Patients
pp. 49-49(1)
Authors: Rose C.; Freue M.; Kjaer M.; Boni C.; Janicke F.; Coombes C.; Willemse P.H.B.; van Belle S.; Carrion R.P.; Jolivet J.; de Palacios P.I.

A Randomised Study Assessing Oestrogen Suppression with Arimidex^TM (Anastrozole) and Formestane in Postmenopausal Advanced Breast Cancer (ABC) Patients
pp. 49-50(2)
Authors: Arimidex Study Group; Dowsett M.; Vorobiof D.A.; Kleeberg U.R.; Carrion R.P.; Dodwell D.J.; Robertson J.F.R.; Calvo L.

Paclitaxel (P) Versus Doxorubicin (D) as First Line Chemotherapy (CT) in Advanced Breast Cancer (ABC): A Randomized Trial with Crossover of the EORTC-IDBBC in Collaboration with EORTC-ECSG
pp. 50-50(1)
Authors: Bruning P.; Piccart M.J.; Klijn J.; Gamucci T.; Kusenda Z.; Roy J.A.; Van Vreckem A.; Paridaens R.

Assessment of Response in Bone within an EORTC Randomised Trial of Bisphosphonate Treatment (10924)
pp. 50-50(1)
Authors: EORTC Breast Group.; Vinholes J.; Coleman R.; Lacombe D.; Mignolet F.; Rose C.; Leonard R.; Nortier J.; Tuibiana-Hulin M.

Reduction of Skeletal Related Complications in Breast Cancer Patients with Osteolytic Bone Metastases Receiving Hormone Therapy, by Monthly Pamidronate Sodium (AREDIA(R)) Infusion
pp. 50-50(1)
Authors: Theriault R.; Lipton A.; Leff R.; Gluck S.; Stewart J.; Costello S.; Simeone J.; Seaman J.; Knight R.; Heffernan M.; Reitsma D.

Reduction of Skeletal Related Complications in Breast Cancer Patients with Osteolytic Bone Metastases Receiving Chemotherapy (CT), by Monthly Pamidronate Sodium (PAM) (AREDIA(R)) Infusion
pp. 50-50(1)
Authors: Hortobagyi G.N.; Porter L.; Blayney D.; Theriault R.L.; Lipton A.; Gluck S.; Wheeler H.; Allan S.; Simeone J.; Seaman J.; Knight R.; Heffernan M.; Reitsma D.

Breast Cancer in 1980-1995: Meta-Analysis of Dose Intensity (Neoadjuvant Chemotherapy)
pp. 50-50(1)
Author: Shparik J.

Half Body (HBI) and Total Body (TBI) Irradiation in Disseminated Breast Cancer Patients (PTS)
pp. 50-51(2)
Authors: Vinogradov V.; Koritova L.

Unclear Value of Salvage Chemotherapy After Failure to First-Line 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) Regimen for Metastatic Breast Cancer
pp. 51-51(1)
Authors: Gardin G.; Campora E.; Gasco M.; Conte P.F.; Rosso R.

Chemoradiotherapy in Complex Treatment of Locally Advanced Breast Cancer
pp. 51-51(1)
Authors: Letyagin V.; Shomova M.; Visotskaya I.; Bogatyrev V.; Zautashvili Z.; Pogodina E.; Shomova N.; Ratiani M.

Five-Year Results of a Multimodal Management of Stage III B Breast Cancer
pp. 51-51(1)
Authors: Massidda B.; Ionta M.T.; Foddi M.R.; Cabula C.; Tarquini A.

Phase II Studies with Rivizor(R) (Vorozole) in Advanced Breast Cancer
pp. 51-51(1)
Authors: Piccart M.; Roy J.A.

Detection of Liver Metastases in Advanced Breast Cancer
pp. 51-51(1)
Authors: Vinholes A.P.B.; Coleman R.E.

Biochemical Markers of Bone Resorption Predict Response to Bisphosphonate Treatment
pp. 51-52(2)
Authors: Vinholes I.; Purohit O.; Eastell R.; Coleman R.

Long-Term Palliation of Metastatic Bone Pain with Intermittent Pamidronate
pp. 52-52(1)
Authors: Zekri I.; Vinholes J.; Purohit O.; Coleman R.

Combination of Intraarterial Chemotherapy with Endocrine Therapy in the Treatment of Liver Metastases of Breast Cancer
pp. 52-52(1)
Authors: Yayoi E.; Maruhashi S.; Tokunaga M.; Masuda N.; Takiguchi S.; Matsui S.; Yano H.; Tateishi H.; Kinuta M.; Maruyama H.; Okamura J.

Epirubicin (E) + Navelbine (NVB) as First Line Chemotherapy in Advanced Breast Cancer (ABC) Patients (PTS): A Multicentric Phase II Study
pp. 52-52(1)
Authors: Baldini E.; Tibaldi C.; Da Prato M.; Chiavacci A.; Di Lieto M.; Taviani R.; Ghezzi P.; Francini G.; Fioretto L.; Michelotti A.; Conte P.F.

Response to Neoadjuvant Chemotheraphy in Locally Advanced Breast Cancer
pp. 52-52(1)
Authors: Purkalne G.; Kudaba I.

Metastatic Dissemination in the Inflammatory Breast Cancer (IBC)
pp. 52-53(2)
Authors: Buric M.; Filipovic S.; Projevic M.; Veselinovic S.

Oral Clodronate for Bone Metastases in Breast Cancer
pp. 53-53(1)
Authors: Projevic M.; Filipovic S.; Veselinovic S.; Buric M.

The Effect of Vorozole on Tissue Aromatase Activity in Advanced Breast Cancer
pp. 53-53(1)
Authors: de Jong P.C.; vd Ven J.; Nortier J.W.R.; Thijssen J.H.H.; Slee P.H.T.J.; Blankenstein M.A.

The Clinical Relevance of Static Disease for 6 Months on Endocrine Therapy in Patients with Breast Cancer
pp. 53-53(1)
Authors: Robertson J.F.R.; Willsher P.; Cheung K.L.; Blamey R.W.

Breast Cancer Bone Metastases Specifically Express Parathyroid Hormone Related Protein (PTHrP) and its Receptor
pp. 53-53(1)
Authors: Downey S.E.; Hoyland J.A.; Freemont A.J.; Bundred N.J.

Analysis of Factors that Improve Quality-of-Life of Patients with Advanced or Recurrent Breast Cancer
pp. 53-53(1)
Authors: Shimozuma K.; Sonoo H.; Ichihara K.

Usefulness of a Combination Chemoendocrine Therapy of Mitoxantrone, Doxifluridine and Medroxyprogesterone Acetate for Anthracycline-Resistant Advanced or Metastatic Breast Cancer
pp. 53-54(2)
Authors: Iino Y.; Yokoe T.; Takei H.; Horiguchi J.; Maemura M.; Ohwada S.; Morishita Y.

Initial Characteristics and Outcome of Infiltrating Lobular Carcinomas (ILC): A Retrospective Study about 737 Patients
pp. 54-54(1)
Authors: Quenel N.; Bourson V.; Durand M.; Dilhuydy J.M.; Mauriac L.; Trojani M.; Bonichon F.

MRF (Mitomycin, Folinic Acid and 5FU) for Metastatic Breast Cancer -- A Prospective Pilot Study
pp. 54-54(1)
Authors: Lange O.F.; Jamitzky T.

Intra-Arterial Liver Chemoinfusion in Patients with Metastatic Breast Cancer
pp. 54-54(1)
Authors: Jamitzky T.; Lange O.F.; Reinartz J.; Beckers C.; Emde H.; Scheef W.

EGR-R in Locally Advanced and Inflammatory Breast Carcinomas
pp. 54-54(1)
Authors: Neskovic-Konstantinovic Z.; Nikolic-Vukosavljevic D.; Kanjer K.; Brankovic-Magic M.; Borojevic N.; Mitrovic I.; Spuzic I.

Chemotherapy for Metastatic Breast Cancer: Ten Years Experience
pp. 54-54(1)
Authors: Piazza E.; Cattaneo M.T.; Tosca N.; Candido P.; Orlandini B.; Gambaro A.; Ferrario S.; Dedor B.; Biancardi D.; Esani G.; Nosenzo M.A.

Metastatic Breast Cancer Management in France
pp. 55-55(1)
Authors: Launois R.; Reboul-Marty J.; Henry B.; Aussage P.; Abella M.L.; Cargill M.

Immunohistochemical Analyses of Proliferative Activity in Breast Carcinomas with Medullary Features
pp. 55-55(1)
Authors: Jensen V.; Jensen M.L.; Kiaer H.; Andersen J.; Melsen F.

The Value of nm23 Protein Expression and Tumor Angiogenesis as a Prognostic Indicator in Breast Cancer of Korean Women
pp. 55-55(1)
Authors: Lee E.S.; Jeong K.H.; Bae J.W.; Koo B.H.; Kim C.H.

Prognostic Value of P21/WAF1 and P53 Expression in Breast Carcinoma: An Immunohistochemical Study on 261 Cases with Long Term Follow Up
pp. 55-55(1)
Authors: Caffo O.; Doglioni C.; Veronese S.; Bonzanini M.; Morelli L.; Palma P.D.; Harris A.L.; Barbareschi M.

The Predictive Value of the Urokinase System of Plasminogen Activation in Recurrent Breast Cancer
pp. 55-56(2)
Authors: Foekens J.A.; Look M.P.; Meijer-van Gelder M.E.; van Putten W.L.J.; Klijn J.G.M.

Expression of uPA, c-erbB2, EGF-R and p53 in 488 Primary Breast Cancer
pp. 56-56(1)
Authors: Spyratos F.; Hacene K.; Le Doussal V.; Durcos L.; Ferrero-Pous M.; Bouchet C.; Rouesse J.

The Use of Molecular Markers to Predict Response to Preoperative Chemotherapy: Fact or Fiction?
pp. 56-56(1)
Authors: van Slooten H.-J.; Elkhuijzen P.; van Dierendonck J.H.; Duval C.; Pallud C.; Denoux Y.; Julien J.P.; Tubiana-Hulin M.; Mandard A.-M.; Leer J.W.H.; van de Velde C.J.H.; van de Vijver M.J.

Immunohistochemical Expression of c-erbB-2, p53, and bcl-2 Oncoprotein and Response to Endocrine Therapy in Advanced Breast Cancer
pp. 56-56(1)
Authors: Osaki A.; Nomura Y.; Tashiro H.; Shirouzu M.; Toge T.

Fatty Acid Synthetase (FAS) and Survival in Breast Cancer
pp. 56-56(1)
Author: Hahnel R.

DNA Image Cytometry (ICM), Oncogenes and Prognostic Factors in Breast Cancer
pp. 56-56(1)
Authors: Schlotter C.M.; Bosse U.; Bosse A.; Vogt U.; Brandt B.; Bruning T.

The Prognostic Significance of Protein Tyrosin Kinase, ER, PR, and the Mitotic Activity Index in 86 Primary Breast Cancer Patients
pp. 57-57(1)
Authors: Bayrak J.; Blankenstein M.A.; Hennipman A.; Rijksen G.; Gimbrere C.; Struikmans H.

Oncogene Evaluation (c-int2, c-erb B2, c-myc) in 265 Breast Carcinoma pT1-T2, pN0-N1, M0
pp. 57-57(1)
Authors: Bolla M.; Chedin M.; Cunin V.; Winckel P.; Merlin F.; Roth H.; Chambaz E.

Breast Cancer Oestrogen-Receptor Negative Tumors, PS₂ Expression and DFI
pp. 57-57(1)
Authors: Filipovic S.; Filipovic B.; Ilic R.; Djordjevic R.; Vrbic S.; Pejcic I.; Veselinovic S.; Stojanovic D.

High Positive Rate of PS2 Expression in Forefront Intraductal Cancerous Area in Breast Cancer
pp. 57-57(1)
Authors: Yamakawa T.; Morimoto T.; Sasa M.; Numoto S.; Monden Y.

Clinical Significance of Pyrimidine Nucleoside Phosphorylase Staining in Breast Cancer
pp. 57-57(1)
Authors: Tanaka S.; Kimura T.; Miyakawa R.; Kamio T.; Kato T.; Yamamoto K.; Kameoka S.; Hamano K.; Murase S.; Kuramitsu H.

Analysis of Angiogenesis, PCNA, c-er b B-2, and p53 Associated with Long-Term Survival in Japanese Women with Breast Cancer
pp. 57-58(2)
Authors: Kato T.; Kimura T.; Miyakawa R.; Tanaka S.; Muraki H.; Kamio T.; Fujii A.; Yamamoto K.; Kameoka S.; Hamano K.; Kawakami M.

Low and High Molecular Weight Cytokeratins Express the Differentiation of Invasive Breast Carcinoma
pp. 58-58(1)
Authors: Takei H.; Iino Y.; Yokoe T.; Horiguchi J.; Maemura M.; Morishita Y.

PCNA Labeling Index and Expression of pS2 and c-erbB-2 Protein in Primary Breast Cancer
pp. 58-58(1)
Authors: Horiguchi J.; Iino Y.; Takei H.; Maemura M.; Kano T.; Horii Y.; Nagasawa M.; Matsumoto H.; Yokoe T.; Morishita Y.

French Association of Cytometry Quality Control Report on FCM-DNA Content and S-phase Fraction
pp. 58-58(1)
Authors: D'Hautcourt J.-L.; Spyratos F.; Vago P.; Chassevent A.

Communicating the Results of Breast Biopsies Over the Telephone and in Person. Is there a Difference?
pp. 58-58(1)
Authors: Campbell L.; Watkins R.M.; Teasdale C.

Evaluation of Quality of Life After Conservative Treatment for Intraductal Carcinoma of the Breast
pp. 58-58(1)
Authors: Caffo O.; Amichetti M.; Arcicasa M.; Roncadin M.; Rigon A.; Lora O.; Zini G.; Coghetto F.; Zorat P.L.

Psychologic Impact of Breast Cancer Diagnosis: Coping Strategies
pp. 58-59(2)
Authors: Cousson F.; Dilhuydy J.M.; Bruchon-Schweitzer M.

Breast Care Nursing Intervention Survey
pp. 59-59(1)
Authors: Cotton P.; Richards C.

Involving a Trained Psychologists at the Time of Breast Cancer (BC) Surgery: Effects on Communication and Psychosocial Adjustment
pp. 59-59(1)
Authors: Aimont M.; Liebens F.; Cluydts N.; Pastijn A.; Vandromme J.; Rozenberg S.; Degueldre M.